There is HOPE.
For help, call
Contact Us for more information.
The Lindner Center of HOPE’s research staff is comprised of nationally and internationally regarded clinical scientists. Each Lindner Center of HOPE researcher has published extensively on a variety of topics.
Paul E. Keck, Jr. MD, President and CEO
Susan L. McElroy, MD, Chief Research Officer
John Hawkins, MD, Chief of Psychiatric Services
Prevalence and correlates of eating disorders in 875 patients with bipolar disorder
Susan L. McElroy, MD
Relatively little is known about the co-occurrence of bipolar and eating disorders. We therefore assessed the prevalence and clinical correlates of eating disorders in 875 patients with bipolar disorder.
A Double-Blind, Placebo-Controlled Study of Quetiapine and Paroxetine as Monotherapy in Adults With Bipolar Depression (EMBOLDEN II)
Susan L. McElroy, MD; Richard H. Weisler, MD; William Chang, PhD; Bengt Olausson, MD; Björn Paulsson, MD; Martin Brecher, MD; Vasavan Agambaram, MD; ...
The aim of this study was to evaluate the efficacy and tolerability of quetiapine and paroxetine monotherapy for major depression and bipolar disorder.
Sodium Oxybate in the Treatment of Binge Eating Disorder: An Open-Label, Prospective Study
Susan L. McElroy, MD, Anna I. Guerdjikova, PhD, Erin L. Winstanley, PhD, Anne M. O’Melia, MD, Nicole Mori, CNP, Paul E. Keck Jr., MD James I. Hudson, MD, ScD
To assess preliminarily the effectiveness of sodium oxybate in binge eating disorder.
Source: International Journal of Eating Disorders
Role of Antiepileptic Drugs in the Management of Eating Disorders
Susan L. McElroy, Anna I. Guerdjikova, Brian Martens, Paul E. Keck Jr, Harrison G. Pope and James I. Hudson
Growing evidence suggests that antiepileptic drugs (AEDs) may be useful in managing some eating disorders. In the present paper, we provide a brief overview of eating disorders, the rationale for using AEDs in the treatment of these disorders and review the data supporting the effectiveness of specific AEDs in the treatment of patients with eating disorders. In addition, the potential mechanisms of action of AEDs in these conditions are discussed.
Source: CNS Drugs
Obesity in Patients With Severe Mental Illness: Overview and Management
Susan L. McElroy, MD
Obesity and overweight are growing health concerns for the general population and a rapidly increasing concern for clinical populations, particularly patients with severe mental illnesses such as schizophrenia and bipolar disorder.
Binge Eating Disorder Pharmacotherapy Clinical Trails—Who Is Left Out?
Anna I. Guerdjikova & Susan L. McElroy
This report examined the characteristics of subjects interested in binge eating disorder (BED) pharmacotherapy trails who were ineligible for participation.
Source: Wiley InterScience
Olanzapine in the Treatment of Pathological Gambling: A Negative Randomized Placebo-Controlled Trial
Susan L. McElroy, M.D.; Erik B. Nelson, M.D.; Jeffrey A. Welge, Ph.D.; Laura Kaehler, B.A.; and Paul E. Keck, Jr., M.D.
Pathological gambling is associated with bipolar disorder and dopamine dysfunction. Olanzapine is a second-generation antipsychotic with mood-stabilizing properties and antagonistic activity at several dopamine receptors. The purpose of this study was to evaluate olanzapine in the treatment of pathological gambling.
We are now recruiting patients for research studies.
To contact us online, click here
Call us at